Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer-Reference-Cited by-同舟云学术

Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer

Published:2019-04-05 Issue:10 Volume:79 Page:2580-2592
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Li Shangze^ORCID,Fong Ka-wing,Gritsina Galina,Zhang Ali,Zhao Jonathan C.,Kim Jung,Sharp Adam,Yuan Wei,Aversa Caterina,Yang Ximing J.,Nelson Peter S.,Feng Felix Y.,Chinnaiyan Arul M.,de Bono Johann S.,Morrissey Colm,Rettig Matthew B.,Yu Jindan

Funder

American Cancer SocietyAmerican Cancer Society (ACS)

Prostate Cancer FoundationProstate Cancer Foundation (PCF)

HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI)

U.S. Department of DefenseU.S. Department of Defense (DOD)

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overexpression of DUSP26 gene suppressed the proliferation, migration, and invasion of human prostate cancer cells;Experimental Cell Research;2024-10

2. Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer;European Journal of Medical Research;2024-08-22

3. SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer;Cancer Letters;2024-08

4. LncRNA LOC730101 Promotes Darolutamide Resistance in Prostate Cancer by Suppressing miR-1-3p;Cancers;2024-07-20

5. Cancer-associated fibroblasts and prostate cancer stem cells: crosstalk mechanisms and implications for disease progression;Frontiers in Cell and Developmental Biology;2024-07-18